

Bright Lisa  
Form 4  
October 03, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Bright Lisa

(Last) (First) (Middle)

C/O INTERCEPT  
PHARMACEUTICALS, INC., 10  
HUDSON YARDS, FLOOR 37

(Street)

NEW YORK, NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
INTERCEPT  
PHARMACEUTICALS, INC.  
[ICPT]

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/24/2017

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)

President, International

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount (A) or Price (D)		
Common Stock	11/24/2017		F		247 <u>(1)</u> D \$ 63.2	26,535 <u>(3)</u>	D
Common Stock	12/18/2017		F		414 <u>(1)</u> D \$ 62.08	26,535 <u>(3)</u>	D
Common Stock	01/01/2018		F		935 <u>(1)</u> D \$ 58.42	26,535 <u>(3)</u>	D
Common Stock	01/08/2018		F		414 <u>(1)</u> D \$ 53.66	26,535 <u>(3)</u>	D

Edgar Filing: Bright Lisa - Form 4

Common Stock	02/24/2018	F	247 <sup>(1)</sup>	D	\$ 62.04	26,535 <sup>(3)</sup>	D
Common Stock	04/01/2018	F	522 <sup>(1)</sup>	D	\$ 61.52	26,535 <sup>(3)</sup>	D
Common Stock	05/24/2018	F	247 <sup>(1)</sup>	D	\$ 69.76	26,535 <sup>(3)</sup>	D
Common Stock	05/31/2018	A	879 <sup>(2)</sup>	A	\$ 0	26,535 <sup>(3)</sup>	D
Common Stock	05/31/2018	F	414 <sup>(1)</sup>	D	\$ 70.21	26,535 <sup>(3)</sup>	D
Common Stock	07/01/2018	F	521 <sup>(1)</sup>	D	\$ 83.91	26,535 <sup>(3)</sup>	D
Common Stock	08/24/2018	F	247 <sup>(1)</sup>	D	\$ 108.45	26,535 <sup>(3)</sup>	D
Common Stock	10/01/2018	F	521 <sup>(1)</sup>	D	\$ 126.46	26,535 <sup>(3)</sup>	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Transaction (Instr. 3)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	--

Date Exercisable	Expiration Date	Title	Amount or Number of Shares
------------------	-----------------	-------	----------------------------

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director      10% Owner      Officer      Other

Bright Lisa  
C/O INTERCEPT PHARMACEUTICALS, INC.  
10 HUDSON YARDS, FLOOR 37  
NEW YORK, NY 10001

President,  
International

## Signatures

/s/ Mark Pruzanski, as  
attorney-in-fact

10/03/2018

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock.
- (2) Represents shares of restricted stock that vested upon the achievement of certain performance milestones.
- (3) In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.